Glenmark Pharmaceuticals ltd — Capital/Financing Update 2020

Dec 9, 2020

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

This announcement is for information purposes only and has not been and will not be registered as a prospectus or a statement in lieu of prospectus with any Registrar of Companies in India and is not and should not be construed as an offering circular, an offering memorandum, an advertisement, a solicitation, an offer or an offer document under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India, the United States or any other jurisdiction. and is not an offer to sell or the solicitation of an offer to acquire, purchase or subscribe for securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever.

December 9, 2020

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001.

To,

The Manager – Listing, The National Stock Exchange of India Ltd., Bandra Kurla Complex, Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Re: Intimation under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR")

This is in furtherance to our earlier letter, intimating you of issuance of a notice of optional redemption (“ Notice ”) in respect of U.S $200 million 4.5% Senior Notes due 2021 (“ 2021 Notes ”) which are listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee.

The Company wishes to inform that the Company has redeemed U.S. $182,500,000 in aggregate principal amount of its 2021 Notes, representing approximately 91.25% of the aggregate principal amount of the 2021 Notes at the time of initial listing. As on the date of this announcement, U.S. $ 17,500,000 in aggregate principal amount of the 2021 Notes remain outstanding.

We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK KUBER VINAYAK KUBER Date: 2020.12.09 18:35:06 +05'30' Harish Kuber

Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma .com